• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado–Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies
【2h】

Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado–Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies

机译：通过病理生物标志物和治疗策略的整合确定3型脊髓小脑共济失调/马查多–约瑟夫病的治疗目标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3/MJD) is a progressive motor disease with no broadly effective treatment. However, most current therapies are based on symptoms rather than the underlying disease mechanisms. In this review, we describe potential therapeutic strategies based on known pathological biomarkers and related pathogenic processes. The three major conclusions from the current studies are summarized as follows: (i) for the drugs currently being tested in clinical trials; a weak connection was observed between drugs and SCA3/MJD biomarkers. The only two exceptions are the drugs suppressing glutamate-induced calcium influx and chemical chaperon. (ii) For most of the drugs that have been tested in animal studies, there is a direct association with pathological biomarkers. We further found that many drugs are associated with inducing autophagy, which is supported by the evidence of deficient autophagy biomarkers in SCA3/MJD, and that there may be more promising therapeutics. (iii) Some reported biomarkers lack relatively targeted drugs. Low glucose utilization, altered amino acid metabolism, and deficient insulin signaling are all implicated in SCA3/MJD, but there have been few studies on treatment strategies targeting these abnormalities. Therapeutic strategies targeting multiple pathological SCA3/MJD biomarkers may effectively block disease progression and preserve neurological function.
机译：脊髓小脑性共济失调3型/马查多–约瑟夫病（SCA3 / MJD）是一种进行性运动疾病，尚无广泛有效的治疗方法。但是，当前大多数疗法都是基于症状而不是潜在的疾病机制。在这篇综述中，我们描述了基于已知病理生物标志物和相关致病过程的潜在治疗策略。当前研究的三个主要结论总结如下：（i）目前正在临床试验中测试的药物；在药物和SCA3 / MJD生物标志物之间观察到弱连接。仅有的两个例外是抑制谷氨酸诱导的钙内流和化学伴侣的药物。 （ii）对于大多数在动物研究中测试过的药物，其与病理生物标志物直接相关。我们进一步发现，许多药物与诱导自噬有关，这由SCA3 / MJD中自噬生物标志物不足的证据支持，并且可能会有更有前途的疗法。 （iii）一些报告的生物标志物缺乏相对针对性的药物。低血糖利用，氨基酸代谢改变和胰岛素信号传导不足均与SCA3 / MJD有关，但针对这些异常的治疗策略的研究很少。针对多种病理性SCA3 / MJD生物标志物的治疗策略可有效阻断疾病进展并保持神经功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号